Marketing-authorisation holder · Canada
Novartis Pharmaceuticals Canada Inc
286 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
286 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 286
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AFINITOR5 mg · Tablet | Everolimus | Canada | Marketed | 2010 |
| AFINITOR10 mg · Tablet | Everolimus | Canada | Marketed | 2010 |
| AFINITOR2.5 mg · Tablet | Everolimus | Canada | Marketed | 2011 |
| AFINITOR DISPERZ5 mg · Tablet For Suspension | Everolimus | Canada | Marketed | 2014 |
| AFINITOR DISPERZ2 mg · Tablet For Suspension | Everolimus | Canada | Marketed | 2014 |
| AFINITOR DISPERZ3 mg · Tablet For Suspension | Everolimus | Canada | Marketed | 2014 |
| AIMOVIG70 mg / ml · Solution | Erenumab | Canada | Marketed | 2018 |
| AIMOVIG140 mg / ml · Solution | Erenumab | Canada | Marketed | 2019 |
| AIMOVIG70 mg / ml · Solution | Erenumab | Canada | Authorised | |
| AIMOVIG140 mg / ml · Solution | Erenumab | Canada | Authorised | |
| ALOMIDE0.1 % / w/v · Solution | Lodoxamide | Canada | Marketed | 1992 |
| ATECTURA BREEZHALER150 mcg + 320 mcg · Capsule | Indacaterol, Mometasone | Canada | Marketed | 2020 |
| ATECTURA BREEZHALER150 mcg + 160 mcg · Capsule | Indacaterol, Mometasone | Canada | Marketed | 2020 |
| ATECTURA BREEZHALER150 mcg + 80 mcg · Capsule | Indacaterol, Mometasone | Canada | Marketed | 2020 |
| AZARGA1 % / w/v + 0.5 % / w/v · Suspension | Brinzolamide, Timolol | Canada | Marketed | 2009 |
| AZOPT1 % / w/v · Suspension | Brinzolamide | Canada | Marketed | 1998 |
| BEOVU6 mg / 0.05 ml · Solution | Brolucizumab | Canada | Marketed | 2020 |
| BEOVU6 mg / 0.05 ml · Solution | Brolucizumab | Canada | Authorised | |
| CERTICAN0.25 mg · Tablet | Everolimus | Canada | Authorised | |
| CERTICAN0.5 mg · Tablet | Everolimus | Canada | Authorised | |
| CERTICAN0.75 mg · Tablet | Everolimus | Canada | Authorised | |
| CILOXAN0.3 % / w/v · Solution | Ciprofloxacin | Canada | Marketed | 1992 |
| CILOXAN0.3 % / w/w · Ointment | Ciprofloxacin | Canada | Marketed | 1998 |
| CIPRODEX0.3 % / w/v + 0.1 % / w/v · Suspension | Ciprofloxacin, Dexamethasone | Canada | Marketed | 2004 |
| COSENTYX150 mg / ml · Solution | Secukinumab | Canada | Marketed | 2024 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 286 | 158 | 128 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.